the tumor and will be measured by a change in tumor size. This change is completely 
dependent on the efficacy of transduction and is not biased by factors such as surgical 
debulking (as is the case in the surgically accessible group) 
Three patients from either group who are considered to have an extremely poor 
prognosis will be included in the first treatment group for assessment of significant toxic 
side effects (which are not expected, based on the various animal studies). The study 
will continue as described if no such toxic effects will be encountered. An evaluation of 
toxicity report will be submitted to the Chairman, ICRS, NINDS, upon the completion of 
the study in these 3 patients. 
Pregnancy testing will be performed on all eligible women. No pregnant 
woman will be entered into the study. HIV screening will be performed by the referring 
physician and patients with HIV infection will not be accepted for this study. 
Confirmatory non-serologic studies for HIV status will be performed at the NIH. 
Recombinant DNA Research, Volume 15 
[805] 
